New Amersham™ WB system for reproducible and quantitative protein analysis The first fully-integrated system based on the traditional Western blotting technique which achieves reliably consistent results with fewer repeats and control experiments Chalfont St Giles, UK — 23 September 2014 – GE Healthcare Life Sciences (NYSE:GE) today launched Amersham WB system, a fully integrated system […]
Data to be Presented at European Society for Medical Oncology Congress in Madrid FOSTER CITY, Calif.–(BUSINESS WIRE)–Sep. 17, 2014– Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from a Phase 2 study evaluating simtuzumab, an investigational inhibitor of lysyl oxidase-like-2 (LOXL2), in combination with gemcitabine for patients with previously untreated advanced pancreatic cancer. In the study, […]
Presentations will include Results from the Phase III coBRIM study of Roche’s investigational MEK inhibitor cobimetinib plus Zelboraf compared to Zelboraf alone, potentially paving the way for a new standard of care Final survival data from the Phase III CLEOPATRA study of the combination of Perjeta, Herceptin and chemotherapy, further confirming the potential of this […]
September 8, 2014 – MIAMI–West Kendall Baptist Hospital in Miami has announced the purchase and installation of a highly advanced computed tomography (CT) scanner following a six-month evaluation at the hospital — the clinical trial of the equipment in the United States. With the convergence of whole-organ coverage, image quality, and speed found in GE […]
Wauwatosa, WI, September 3, 2014 — GE Healthcare (NYSE: GE) today announced the FDA approval of SenoClaire*, GE’s new breast tomosynthesis solution designed with a three-dimensional imaging technology. In collaboration with Massachusetts General Hospital, GE developed SenoClaire technology that uses a low-dose short X-ray sweep around the positioned breast with nine exposures acquired with a […]
Highlights Impact on Cost of Care SUNNYVALE, Calif., Dec. 19, 2013 (GLOBE NEWSWIRE) — A national, multi-institutional database study found readmission and complication rates were significantly lower for robotic-assisted prostate surgery than for open prostate surgery.1 The full study results were published in the November 19 electronic edition of the Journal of Endourology. “Readmissions for Medicare patients alone currently add $17.4 billion each year in […]
Agreement secures full Elekta solution across the McLaren enterprise STOCKHOLM, December 18, 2013 – The ability to effectively manage data across disparate health systems to help drive quality care will be a cornerstone for health systems of the future. Elekta is proud to announce today that it has joined forces with Michigan-based McLaren Health Care […]
PALO ALTO, Calif., Dec. 16, 2013 /PRNewswire/ — Varian Medical Systems (NYSE:VAR) today announced that Robert H. Kluge has announced his intention to retire as its Senior Vice President and President, Imaging Components Businesses effective February 7, 2014. Varian CEO Dow R. Wilson has named and the Board of Directors has appointed Sunny Sanyal, CEO of T-System, to succeed Kluge. Varian’s Imaging Components Businesses […]
57 Percent Overall Response Rate and Median Duration of Response of 12.5 Months in Heavily Pre-Treated Patients Data Presented at American Society of Hematology Annual Meeting NEW ORLEANS, Dec 08, 2013 (BUSINESS WIRE) –Gilead Sciences, Inc. (Nasdaq: GILD) today announced results of a Phase 2 study (Study 101-09) evaluating idelalisib, an investigational oral inhibitor of PI3K […]
Data Presented at the 55th American Society of Hematology Annual Meeting NEW ORLEANS–(BUSINESS WIRE)–Dec. 7, 2013– Gilead Sciences, Inc. (Nasdaq: GILD) today announced interim results from a single-arm, open-label Phase 2 study evaluating GS-9973, an investigational oral inhibitor of spleen tyrosine kinase (Syk), for the treatment of patients with relapsed or refractory hematologic malignancies. The data show that […]